Search

Multi-center acute myeloid leukemia study

An SWG Grant-supported project initiated by EHA's SWG on Acute Myeloid Leukemia.

Standards for functional precision medicine project

An SWG Grant-supported project initiated by EHA's SWG on Precision Hematology.

Splenic marginal zone lymphoma study

An SWG Grant-supported project initiated by the EHA Lymphona Group.

CAR NK-cells project

An SWG Grant-supported project initiated by EHA's SWG on Immune Therapies for Hematologic Disorders.

Publications

This SWG was established in January 2024. Publications will be added in due course.

Highlights from the SWG

This SWG was established in January 2024. Highlights will be added in due course.

SWG educational activities

This SWG was established in January 2024. Educational activities will be added in due course.

Implementation of the new EU Regulation for In Vitro Diagnostic Medical Devices: a ticking time bomb for the diagnostic sector.

May 28 2021

Urgent actions are needed now to prevent a collapse of diagnostic testing.

Adding elotuzumab to standard treatment for multiple myeloma significantly reduced the risk of disease progression, with benefits sustained at two years

Jun 12 2015

ELOQUENT-2, which evaluated elotuzumab in combination with lenalidomide and dexamethasone, is the first Phase III study to demonstrate the benefit of directly activating the immune system in the treatment of patients with relapsed or refractory multiple myeloma.